Skip to content

Neopterin levels in saliva of patients with gum disease.

Comparative Evaluation of Salivary Neopterin levels as Compared to MMP-8 levels in Periodontitis patients- An Observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/052692
Enrollment
65
Registered
2023-05-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Group IIA Group IIB: GROUP IIA- patients with Stage I and Stage II periodontitis. GROUP II B- Patients with stage III and Stage IV periodontitis Intervention2: Group 1: Healthy control:

Sponsors

DR SHRUTI KALBAGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I)Inclusion Criteria: 1. a) Patients who are 25 to 65years and above who are willing to participate.b) Presence of at least 20 natural teeth excluding third molars. c) Chronic periodontitis as stated by American Academy of Periodontology (AAP) classification 2017: presence of > 2 teeth in each quadrant with a PPD of and radiographic evidence of interproximal bone loss. Along with BOP at >50% of sites of full mouth. II) a) Patients who are 25 to 65years and above who are willing to participate.b) Presence of at least 20 natural teeth excluding third molars. c) Chronic periodontitis as stated by American Academy of Periodontology (AAP) classification 2017: presence of > 2 teeth in each quadrant with a PPD of >6mm, CAL of >5mm and radiographic evidence of interproximal bone loss. Along with BOP at >50% of sites of full mouth.

Exclusion criteria

Exclusion criteria: II) Exclusion Criteria: a) Patients with any other known systemic disorders. b) Patients who have received any form of periodontal therapy, surgical or non-surgical within past 6 months. c) Patients who have received any antibiotic or anti-inflammatory drug regimen within past 6 months. d) Patients who smoke or chew any form of tobacco. e) Patients who are pregnant or lactating. f) Patients who are undergoing any orthodontic treatment. g) Physically and mentally challenged patients. h) Patients prone to or with a history of allergic reactions to any component of the investigating materials.

Design outcomes

Primary

MeasureTime frame
Baseline diagnostic clinical parameters [PD, CAL and BOP] and Salivary MMP 8 and neopterin levelsTimepoint: Baseline diagnostic assessment point as sole assessment point

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDR VINEET KINI

MGM DENTAL COLLEGE AND HOSPITAL, NAVI MUMBAI

drvinkin@gmail.com9769804390

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026